Cancer clinical trials in the region Île-de-France

787 currently recruiting clinical trials
Region Île-de-France
Phase 1 / Phase 2 Acute leukemia #NCT04256317
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy Targeted therapy Car-T
3 recruiting sites
Taiho Oncology
Phase 1 / Phase 2 Multiple myeloma #NCT04643002 #2020-003024-16
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Monoclonal antibodies Proteasome inhibitor Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive Allogeneic stem cell transplant
4 recruiting sites
Sanofi
Phase 1 / Phase 2 Multiple myeloma #NCT04643002 #2020-003024-16
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Monoclonal antibodies Proteasome inhibitor Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Sanofi
Phase 1 / Phase 2 Multiple myeloma #NCT04643002 #2020-003024-16
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Proteasome inhibitor Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive Allogeneic stem cell transplant
4 recruiting sites
Sanofi
Phase 1 / Phase 2 Multiple myeloma #NCT04643002 #2020-003024-16
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Proteasome inhibitor Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Sanofi
Phase 1 / Phase 2 Multiple myeloma #NCT04643002 #2020-003024-16
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Proteasome inhibitor Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Sanofi
Phase 1 / Phase 2 Multiple myeloma #NCT04643002 #2020-003024-16
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Proteasome inhibitor Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Sanofi
Phase 1 / Phase 2 Liver and bile duct cancer #NCT07291076 #2025-523602-33-00
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Bristol-Myers Squibb
Phase 1 / Phase 2 Lung cancer #NCT06892548 #2024-520238-31-00
Required histologic types
SCLC (Small Cell Lung Cancer) NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2 Lung cancer #NCT06892548 #2024-520238-31-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ALK BRAF EGFR HER2 KRAS G12C MET NTRK-1/2/3 RET ROS-1
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE